Norway: Medical Cannabis Market Overview 2025

Medical cannabis in Norway is available only under strict exemption procedures administered by the Norwegian Medicines Agency (DMP). Since November 2016, when new medical cannabis and approval exemption guidelines were issued, unregistered cannabis-based products — including flowers and oils containing more than 1% THC — have been accessible to patients only through specialist-approved exemptions.

While this system enables limited patient access, it remains highly restrictive and case-specific, with each prescription requiring DMP approval. Norway has no domestic cultivation or production, and all cannabis-based medicines are imported under licence.

There is no established commercial medical cannabis market, and patient numbers remain low. However, the framework allows for pharmaceutical-grade imports of recognised EU-GMP-certified products, ensuring safety and quality compliance.

Norway’s medical cannabis system operates under the Medicines Act (Legemiddelloven) and the Narcotics Regulations (Forskrift om narkotika), both overseen by the Norwegian Medicines Agency (DMP).

Approval Process for Unregistered Cannabis Medicines:

Oversight:

The exemption model ensures that medical cannabis use remains exceptional rather than routine.

Who Can Prescribe? Only medical specialists (e.g., pain management, oncology, neurology) can prescribe unregistered medical cannabis products through DMP exemption. General practitioners cannot prescribe cannabis-based medicines.

Prescribing Criteria:

Conditions Commonly Treated: While there is no official list of indications, exemptions are typically granted for:

Dispensation:

Reimbursement:

Available Products (Unregistered):

All products are EU-GMP certified and supplied through licensed pharmaceutical channels.

Domestic Production: There is no domestic cultivation, extraction, or processing of medical cannabis in Norway.

Imports: Products are imported primarily from Denmark and the Netherlands under specific DMP exemptions.

Norway’s medical cannabis framework is one of the most clinically conservative in Europe, designed to ensure patient safety through tight regulatory oversight and limited prescribing privileges.

While patient access has improved slightly since 2016, the system remains bureaucratic and slow-moving, with approvals often taking several weeks. The lack of an authorised medical cannabis product on the Norwegian market further constrains growth.

However, increasing dialogue within Norway’s medical community — particularly around chronic pain management — suggests potential for gradual evolution. The country’s participation in Nordic supply chains via Denmark could also facilitate improved availability and clinical familiarity in the future.

Until formal product authorisations or broader prescribing rights are introduced, Norway’s market will remain small, import-dependent, and exemption-driven.

Get granular market sizing forecasts, patient population data, and competitive intelligence across 31 European markets. Trusted by investors, operators, and regulators across the continent.